Home › Funds › PFM Health Sciences, LP › BBIO

PFM Health Sciences, LP position in BBIO

BRIDGEBIO PHARMA INC · Health Care

PFM Health Sciences, LP reported holding 253,358 shares of BBIO (BRIDGEBIO PHARMA INC) in its Q2 2026 13F filing — a position valued at US$18.9M, representing 1.65% of its reported portfolio and ranking #16 among its reported holdings. PFM Health Sciences, LP has disclosed BBIO holdings in 7 of the last 7 reported quarters, going back to Q4 2024.

Latest position (Q2 2026)253.36K sh
Reported value held$18.87M
Portfolio Weight1.65%
First reportedQ4 2024
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How PFM Health Sciences, LP's BBIO position evolved

PFM Health Sciences, LP first disclosed a stake in BBIO in Q4 2024 at 50,000 shares (US$1.4M). The position peaked in Q1 2025 at 908,135 shares, worth US$31.4M. Across 7 filings, PFM Health Sciences, LP increased the stake 1 time(s), trimmed it 5 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 253,358 shares valued at US$18.9M — a reduction of -4,389 shares quarter over quarter.. Notable position changes include a 1716% increase in Q1 2025 (shares rose 25% over the following quarter), a 43% trim in Q2 2025 (shares rose 20% over the following quarter), a 37% trim in Q3 2025 (shares rose 47% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2024 50.00K $1.37M New
Q1 2025 908.13K $31.39M Add
Q2 2025 521.79K $22.53M Reduce
Q3 2025 327.17K $16.99M Reduce
Q4 2025 306.51K $23.44M Reduce
Q1 2026 257.75K $19.14M Reduce
Q2 2026 253.36K $18.87M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BBIO and 13F data

BBIO (BRIDGEBIO PHARMA INC) is a Health Care company. 48 other funds we track also report a position in BBIO — the largest reported positions include Jupiter Topco LLC (US$1.05B), Janus Henderson Group (US$978.6M), Farallon Capital Management (US$800.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BBIO

All BBIO fund holders →

FAQ

How long has PFM Health Sciences, LP held BBIO?

PFM Health Sciences, LP has disclosed BBIO holdings in 7 of the last 7 reported quarters, going back to Q4 2024.

What is PFM Health Sciences, LP's current position in BBIO?

As of Q2 2026, PFM Health Sciences, LP holds 253.36K shares of BBIO (BRIDGEBIO PHARMA INC), valued at $18.87M, representing 1.65% of its reported portfolio and ranking #16.

Has PFM Health Sciences, LP been buying or selling BBIO?

In the latest 13F filing (Q2 2026), PFM Health Sciences, LP reduced its position in BBIO. The position peaked in Q1 2025 at 908.13K shares.

Which other funds hold BBIO?

Other major institutional holders of BBIO include Jupiter Topco LLC, Janus Henderson Group, Farallon Capital Management, among 48 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.